Home
This site is intended for healthcare professionals

Key Clinical Summary: Addressing Clinical Inertia and Complex Polypharmacy

This is a micro-learning module summary of a presentation by Prof. Chris Cannon which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This program is supported through an independent educational grant from MSD. It is intended for healthcare professionals globally.

Introduction

Despite clear evidence and well-established guidelines, lipid-lowering therapy remains underused and undertitrated in routine clinical practice. This summary examines the key clinical, system-level, and patient-related factors that limit guideline implementation and outlines practical strategies to support more consistent, risk-based lipid management.

Why guidelines are not consistently followed

Despite strong evidence supporting LDL-C lowering, guideline implementation remains inconsistent. A major contributor has been historical uncertainty introduced by the 2013 ACC/AHA recommendations, which moved away from LDL-C treatment targets in favor of fixed-intensity statin therapy. This shift created confusion in clinical practice and slowed treatment intensification. Subsequent guideline updates, including the 2018 ACC/AHA and the ESC/EAS guidelines, have re-established LDL-C targets aligned to patient risk, restoring a clearer and more actionable treatment framework.

Limited awareness of non-statin lipid-lowering therapies has further constrained optimal care. While statins are widely recognised, knowledge gaps remain among clinicians and patients regarding the role of ezetimibe, PCSK9 inhibitors, bempedoic acid, and other agents, particularly in patients who do not achieve LDL-C targets on statins alone.

Clinical inertia also contributes to undertreatment. Patients who appear clinically stable are often reviewed infrequently, and opportunities to intensify therapy may be missed. System-level constraints, including limited visit time and insufficient follow-up infrastructure, further reduce the likelihood of timely treatment adjustments.

Patient-level barriers are common and include concerns about statin-associated muscle symptoms, reluctance to take long-term medications, and exposure to misinformation that questions the role of cholesterol in cardiovascular disease. These factors can delay or prevent initiation and escalation of lipid-lowering therapy, particularly in primary prevention.

Guideline evolution and re-establishment of LDL-C targets

Contemporary European and US guidelines emphasise matching LDL-C targets to cardiovascular risk. The ESC/EAS guidelines have consistently maintained this risk-based approach, recommending progressively lower LDL-C targets as risk increases. Recent ACC/AHA guidance has moved in the same direction, including recommendations to intensify therapy in patients with recent acute coronary syndrome when LDL-C remains above goal despite maximally tolerated statin therapy. This convergence supports a treat-to-target strategy in both primary and secondary prevention.

System-based approaches to improve lipid management

System-level solutions can address barriers related to time, follow-up, and clinical inertia. Team-based care models that incorporate patient navigators, pharmacists and remote care teams allow more frequent monitoring of lipid levels, structured medication titration, and systematic assessment of drug–drug interactions. Digital tools can support risk stratification, treatment decisions, and communication, enabling care delivery beyond the traditional annual specialist visit.

These approaches have demonstrated substantial LDL-C reductions among patients who engage with structured remote management programmes, highlighting the potential impact of care redesign on population-level lipid control.

Structured management of statin intolerance

A stepwise approach to statin intolerance supports continued LDL-C lowering while maintaining patient engagement. This includes shared decision-making, evaluation for alternative causes of symptoms, temporary statin discontinuation followed by rechallenge, and use of ultra-low-dose or non-daily statin regimens. When statins are not tolerated despite these measures, non-statin therapies provide effective alternatives to achieve LDL-C reduction.

Role of coronary artery calcium imaging in primary prevention

Coronary artery calcium (CAC) scoring is a valuable tool in primary prevention when treatment decisions are uncertain. CAC imaging provides direct evidence of subclinical atherosclerosis and integrates cumulative lifetime risk exposure. A CAC score of zero identifies patients at very low short- and intermediate-term risk, in whom lipid-lowering therapy may be deferred with reassessment over time. Conversely, detection of coronary calcification supports treatment initiation and intensification by demonstrating existing atherosclerotic burden.

CAC assessment can also be derived opportunistically from non–ECG-gated CT scans performed for other indications, further expanding its clinical utility. By visualising disease presence or absence, imaging can improve patient understanding, reduce uncertainty, and facilitate shared decision-making, particularly among younger patients, statin-intolerant individuals, and those reluctant to initiate therapy.

Summary

In 2025, LDL-C lowering strategies are guided by cardiovascular risk and treatment context. In primary prevention, statins remain first-line therapy, with ezetimibe or bempedoic acid as alternatives, targeting LDL-C <100 mg/dL. In patients with low calculated ASCVD risk where treatment decisions are uncertain, coronary artery calcium scoring can refine risk assessment, with CAC=0 supporting deferral of statin therapy and elevated CAC prompting treatment as ASCVD. For patients with established ASCVD, combination lipid-lowering therapy is recommended to achieve LDL-C <70 mg/dL, with more aggressive targets (<55 mg/dL) in very high-risk populations. Structured approaches to statin intolerance and the availability of multiple non-statin agents support individualized care, with further guideline updates and new LDL-lowering therapies anticipated in 2026.

Content is accurate as of the date of release.